Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830776 · ClinicalTrials.gov registry record · Early Phase 1
Topical Bimatoprost for Chemical Blepharoplasty
A Early Phase 1 study, sponsored by Tulane University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT02830776 is a Early Phase 1 study that has completed, run by Tulane University. The registered enrollment target is 15 participants.
The verdict
NCT02830776, a Early Phase 1 study, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Topical bimatoprost has been shown to cause periorbital changes of soft tissue which are most pronounced when used directly onto the cornea for the treatment of glaucoma. Changes are primarily felt to be the result of prostaglandin-mediated adipocyte loss, resulting in deepening of the upper eyelid sulcus and recession of infraorbital pseudoherniation. Use of topical bimatoprost to the upper eyelid margin, now FDA approved for eyelash enhancement, may provide a metered effect on the periocular tissues and allow for a topical approach to periocular rejuvenation. This is a proof of concept study which aims to enroll a series of patients with mild to severe dermatochalasis, treat with topical bimatoprost 0.03% solution to the upper lid margin, and evaluate for cosmetic improvement of the periocular area.
Interventions
- DRUG bimatoprost 0.03% ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02830776
The ClinicalTrials.gov registry entry for NCT02830776 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bimatoprost 0.03% ophthalmic solution is the first listed.
NCT02830776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02830776 about?
NCT02830776 is a clinical study titled "Topical Bimatoprost for Chemical Blepharoplasty". Topical bimatoprost has been shown to cause periorbital changes of soft tissue which are most pronounced when used directly onto the cornea for the treatment of glaucoma. Changes are primarily felt to be the result of prostaglandin-mediated adipocyte loss, resulting in deepening of the upper eyelid ...
What is the current status of trial NCT02830776?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2016-11. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02830776?
The interventions under investigation include: bimatoprost 0.03% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02830776?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.